Lilly sues to block copy of Evista osteoporosis drug

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. sued Watson Pharmaceuticals Inc. to prevent the sale of a generic version of its osteoporosis drug Evista in the United States.

Watson, based in Corona, Calif., filed for U.S. Food and Drug Administration approval to sell a low-cost version of the Lilly medicine, which contains the active ingredient raloxifene hydrochloride. Indianapolis-based Lilly is seeking a court order that would block approval until three of its patents expire in 2017.

Evista is a bone-loss treatment first approved by regulators in 1997 and used to treat women after menopause. A study released last month indicated that raloxifene also may provide some protection against breast cancer in women. The drug generated $682.2 million in U.S. sales last year for Lilly, the company said Jan. 28.

In its FDA application, Watson contends the patents are invalid, unenforceable or not infringed, according to a complaint filed by Lilly on May 3 in federal court in Indianapolis.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ